Savings from sub-groups? Policy guidance and Alzheimer's disease treatments

P. McNamee, A. Vanoli, D. Hutchings, I. Mckeith, J. Bond

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A range of new therapeutic agents are now available for the management of Alzheimer's disease. With limited resources available however, policy-makers and other health care professionals have to prioritise and judge competing treatments on criteria such as the magnitude of clinical effectiveness and cost-effectiveness. Policy guidance that restricts treatments to defined patient sub-groups can improve the cost-effectiveness of treatments, and can help limit rises in health care expenditures. Budget impact models that estimate the amount of additional costs and potential savings are being increasingly used by policy-makers. However, the amount of savings estimated in such models depends on the effectiveness of treatment in changing morbidity, and the association between morbidity and costs.

To examine the magnitude of cost savings arising from provision of treatment to different patient sub-groups, using policy guidance decisions made by the National Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies in Alzheimer's Disease (AD) in the United Kingdom National Health Service (NHS).

Cohort simulation modelling.

Policy guidance decisions that restricted treatment to smaller patient sub-groups were associated with lower overall care costs, but did not reduce drug costs.

Given increasing recognition by health policy-makers of the importance of affordability of new treatments, greater attention should be paid to measurement of cost impacts by sub-groups within health economic modelling.

Original languageEnglish
Pages (from-to)664-668
Number of pages5
JournalJournal of Nutrition, Health & Aging
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Alzheimer's disease
  • costs
  • cost analysis
  • dementia
  • economics
  • sub-groups
  • budget impact
  • donepezil
  • cholinesterase inhibitor therapies
  • cholinesterase-inhibitors
  • cost-effectivness
  • economic-evaluation
  • mild
  • galantamine
  • survival
  • symptoms
  • efficacy

Cite this

Savings from sub-groups? Policy guidance and Alzheimer's disease treatments. / McNamee, P.; Vanoli, A.; Hutchings, D.; Mckeith, I.; Bond, J.

In: Journal of Nutrition, Health & Aging, Vol. 14, No. 8, 08.2010, p. 664-668.

Research output: Contribution to journalArticle

McNamee, P. ; Vanoli, A. ; Hutchings, D. ; Mckeith, I. ; Bond, J. / Savings from sub-groups? Policy guidance and Alzheimer's disease treatments. In: Journal of Nutrition, Health & Aging. 2010 ; Vol. 14, No. 8. pp. 664-668.
@article{5426ac03e56c42d681e1d33f933f374d,
title = "Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments",
abstract = "A range of new therapeutic agents are now available for the management of Alzheimer's disease. With limited resources available however, policy-makers and other health care professionals have to prioritise and judge competing treatments on criteria such as the magnitude of clinical effectiveness and cost-effectiveness. Policy guidance that restricts treatments to defined patient sub-groups can improve the cost-effectiveness of treatments, and can help limit rises in health care expenditures. Budget impact models that estimate the amount of additional costs and potential savings are being increasingly used by policy-makers. However, the amount of savings estimated in such models depends on the effectiveness of treatment in changing morbidity, and the association between morbidity and costs.To examine the magnitude of cost savings arising from provision of treatment to different patient sub-groups, using policy guidance decisions made by the National Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies in Alzheimer's Disease (AD) in the United Kingdom National Health Service (NHS).Cohort simulation modelling.Policy guidance decisions that restricted treatment to smaller patient sub-groups were associated with lower overall care costs, but did not reduce drug costs.Given increasing recognition by health policy-makers of the importance of affordability of new treatments, greater attention should be paid to measurement of cost impacts by sub-groups within health economic modelling.",
keywords = "Alzheimer's disease, costs, cost analysis, dementia, economics, sub-groups, budget impact, donepezil, cholinesterase inhibitor therapies, cholinesterase-inhibitors, cost-effectivness, economic-evaluation, mild, galantamine, survival , symptoms, efficacy",
author = "P. McNamee and A. Vanoli and D. Hutchings and I. Mckeith and J. Bond",
year = "2010",
month = "8",
doi = "10.1007/s12603-010-0313-5",
language = "English",
volume = "14",
pages = "664--668",
journal = "Journal of Nutrition, Health & Aging",
issn = "1279-7707",
publisher = "Springer Paris",
number = "8",

}

TY - JOUR

T1 - Savings from sub-groups?

T2 - Policy guidance and Alzheimer's disease treatments

AU - McNamee, P.

AU - Vanoli, A.

AU - Hutchings, D.

AU - Mckeith, I.

AU - Bond, J.

PY - 2010/8

Y1 - 2010/8

N2 - A range of new therapeutic agents are now available for the management of Alzheimer's disease. With limited resources available however, policy-makers and other health care professionals have to prioritise and judge competing treatments on criteria such as the magnitude of clinical effectiveness and cost-effectiveness. Policy guidance that restricts treatments to defined patient sub-groups can improve the cost-effectiveness of treatments, and can help limit rises in health care expenditures. Budget impact models that estimate the amount of additional costs and potential savings are being increasingly used by policy-makers. However, the amount of savings estimated in such models depends on the effectiveness of treatment in changing morbidity, and the association between morbidity and costs.To examine the magnitude of cost savings arising from provision of treatment to different patient sub-groups, using policy guidance decisions made by the National Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies in Alzheimer's Disease (AD) in the United Kingdom National Health Service (NHS).Cohort simulation modelling.Policy guidance decisions that restricted treatment to smaller patient sub-groups were associated with lower overall care costs, but did not reduce drug costs.Given increasing recognition by health policy-makers of the importance of affordability of new treatments, greater attention should be paid to measurement of cost impacts by sub-groups within health economic modelling.

AB - A range of new therapeutic agents are now available for the management of Alzheimer's disease. With limited resources available however, policy-makers and other health care professionals have to prioritise and judge competing treatments on criteria such as the magnitude of clinical effectiveness and cost-effectiveness. Policy guidance that restricts treatments to defined patient sub-groups can improve the cost-effectiveness of treatments, and can help limit rises in health care expenditures. Budget impact models that estimate the amount of additional costs and potential savings are being increasingly used by policy-makers. However, the amount of savings estimated in such models depends on the effectiveness of treatment in changing morbidity, and the association between morbidity and costs.To examine the magnitude of cost savings arising from provision of treatment to different patient sub-groups, using policy guidance decisions made by the National Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies in Alzheimer's Disease (AD) in the United Kingdom National Health Service (NHS).Cohort simulation modelling.Policy guidance decisions that restricted treatment to smaller patient sub-groups were associated with lower overall care costs, but did not reduce drug costs.Given increasing recognition by health policy-makers of the importance of affordability of new treatments, greater attention should be paid to measurement of cost impacts by sub-groups within health economic modelling.

KW - Alzheimer's disease

KW - costs

KW - cost analysis

KW - dementia

KW - economics

KW - sub-groups

KW - budget impact

KW - donepezil

KW - cholinesterase inhibitor therapies

KW - cholinesterase-inhibitors

KW - cost-effectivness

KW - economic-evaluation

KW - mild

KW - galantamine

KW - survival

KW - symptoms

KW - efficacy

U2 - 10.1007/s12603-010-0313-5

DO - 10.1007/s12603-010-0313-5

M3 - Article

VL - 14

SP - 664

EP - 668

JO - Journal of Nutrition, Health & Aging

JF - Journal of Nutrition, Health & Aging

SN - 1279-7707

IS - 8

ER -